1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Olon Expands Pipeline With Pralsetinib And Trilaciclib

Announces Two ‘NIBs’ With Proprietary Technology And Patent Filings

 
• By Dave Wallace

API specialist Olon has announced the expansion of its pipeline with the addition of two products: pralsetinib and trilaciclib.

Pipeline metal tube forest
Olon is expanding its pipeline with two new products • Source: Ben Schonewille / Alamy Stock Photo

Italian active pharmaceutical ingredients specialist Olon has announced “a further significant expansion of its generic pipeline” with the addition of two kinase inhibitor “NIBs”: pralsetinib tablets and injectable trilaciclib.

Pralsetinib is indicated for treatment of non-small cell lung cancer, while trilaciclib is indicated to decrease the incidence of chemotherapy-induced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.